| Literature DB >> 31832978 |
Maud J M Geerkens1, Nieck S A Pouwels2, Harry P Beerlage2.
Abstract
PURPOSE: The aim of this review is to systematically review randomized controlled trials on lifestyle interventions on PCa patients undergoing androgen deprivation therapy.Entities:
Keywords: ADT; Lifestyle interventions; Males; Prostate cancer; Side effects
Mesh:
Substances:
Year: 2019 PMID: 31832978 PMCID: PMC7142057 DOI: 10.1007/s11136-019-02361-z
Source DB: PubMed Journal: Qual Life Res ISSN: 0962-9343 Impact factor: 4.147
Fig. 1Flow chart of the search and selection process
Study characteristics of the included studies
| Study year | Patients ( | Age (mean) | Inclusion criteria | Interventions | Duration intervention (weeks) + frequency ( | Relevant outcomes | Methods to assess relevant outcomes |
|---|---|---|---|---|---|---|---|
| Segal [ | Int: 82 Con: 73 Total: 155 | Int: 68.2 Con: 67.7 | Local and advanced PCa receiving ADT ≥ 3 months | Supervised resistance exercise | Duration: 12 Frequency: 3 | Fatigue Overweight Quality of life | FACT-F BMI, waist circumference, skinfolds thickness FACT-P |
| Taylor [ | Life: 46 Educ: 51 Con: 37 Total: 134 | Int + Con: 69.2 | PCa treated with ADT | Lifestyle activity program Educational support program | Duration 24 Frequency: week 1–16: 1 4 week: 2 | Overweight Depression Quality of life | BMI: Waist and hip circumferences, waist-hip ratio CES-D SF-36, STAI |
| Sharma [ | Soy: 20 Con: 19 Total 39 | Soy: 69.2 Con: 69.0 | PCa treated with ADT | Soy protein: 20 g | Duration: 12 Frequency: 7 | Fatigue Libido and sexual function Hot flushes Quality of life | SF-36 IIEF, WSFS Blatt-Kupperman scale SF-36 |
| Culos-Reed [ | Int: 53 Con: 47 Total: 100 | Int: 67.2 Con: 68 | PCa localized or metastatic and expect to receive ADT for ≥ 6 months | Supervised and unsupervised aerobic + resistant exercise | Duration: 16 Frequency: 3–5 | Fatigue Overweight Cardiovascular Libido Depression Quality of life | FSS BMI, waist-to-hip ratio RR EPIC CES-D EORTC-QLQ-C30, EPIC |
| Galvao [ | Int: 29 Con: 28 Total: 57 | Int: 69.5 Con: 70.1 | Locally or advanced PCa (without bone metastasis) with prior exposure ADT > 2 months | Supervised aerobic + resistance exercise | Duration: 12 Frequency: 2 | Fatigue Overweight Cardiovascular Insulin resistance Quality of life | QLQ-C30, SF-36 Dual X-ray absorptiometry: total lean body mass, regional lean mass: upper limb, lower limb, appendicular skeletal muscle total fat mass, trunk fat mass, and percentage body fat, Blood samples: total cholesterol, LDL, HDL, triglycerides, CRP 400 m walk Blood samples: Insulin + glucose EORTC-QLQ-C30; SF-36 |
| Bourke [ | Int: 25 Con: 25 Total: 50 | Int: 71.3 Con: 72.2 | Non localized PCa who receiving ADT ≥ 6 months | Supervised + unsupervised aerobic + resistance exercise | Duration: 12 Frequency: Resistance + aerobic: week 1–6: 1; 7–12:2x Eating seminars: 1x | Fatigue Overweight Insulin resistance Quality of life | FACT-F BMI; weight; waist-to-hip ratio Blood biomarkers: insulin; IGF-1 FACT-P; FACT-G |
| Cormie [ | Int: 29 Con: 28 Total: 57 | Int: 69.5 Con: 70.1 | Locally PCa, on ADT ≥ 2 months and remained hypogonadal for ≥ 6 months | Supervised aerobic + resistance exercise | Duration: 12 Frequency: 2 | Libido and sexual function Quality of life | QLQ-PR25 SF-36 |
| Hvid [ | Int: 10 Con: 9 Total: 19 | Int: 67.8 Con: 68.5 | PCa with ADT > 3 months Control group: healthy males | Supervised endurance Exercise | Duration: 12 Frequency: 3 | Overweight Cardiovascular Insulin resistance | Dual x-ray absorptiometry: body lean mass, fat mass, trunk fat mass MR: femoral to liver distance, visceral fat mass, skin fat mass, intermuscular adipose tissue Tissue samples: m. vastus lateralis Blood biomarkers: total cholesterol, LDL, HDL, triglycerides VO2 Max OGTT Euglycemic–hyperinsulinemic clamp Blood samples: glucose, insulin Glucose kinetics calculations |
| Santa Mina [ | Aer: 32 Res: 34 Total: 66 | Aer: 72.1 Res: 70.6 | PCa currently receiving ADT ≥ 12 months | Supervised and unsupervised aerobic or resistance exercise | Duration: 26 Frequency Total: 3–5 Supervised: 1 × 2 week | Fatigue Overweight Gynecomastia Cardiovascular Quality of life | FACT-F BMI, Body fat, waist circumference, body fat: Skinfolds: chest, abdomen + thigh Chest skinfold thickness VO2 max FACT-P; PORPUS |
| Vitolins [ | Soy: 30 Ven: 30 V + S: 30 Con: 30 Total:120 | Soy: 71 Ven: 67 V + S: 69 Con: 67 | Locally advanced or metastatic PCa on ADT and having hot flushes | Soy protein: 20 g Venlafaxine | Duration: 12 Frequency: daily | Hot flashes Quality of life | HFSSS FACT-P; FACT-G |
| Walker [ | Int: 20 Con: 20 Total: 40 | NR | PCa on ADT | Education booklet on side effects Educational review survey | NA | Libido | PAIR inventory: DAS scale Sexual activity |
| Bourke [ | Int: 50 Con: 50 Total: 100 | Int: 71 Con: 71 | Locally advanced or metastatic PCa, previously on ADT ≥ 6 months and planned long term on ADT | Aerobic + resistance Exercise + dietary advice | Duration: 12 Frequency Resistance: week 1–6: 2x; 7–12: 1x Aerobic: week 1-6: 1; 7–12: 2x Dietary: 1 × 2 weeks | Fatigue Overweight Cardiovascular Quality of life | FACT-F BMI; weight Systolic blood pressure, aerobic exercise tolerance FACT-P |
| Uth [ | Int: 29 Con: 28 Total: 57 | Int: 67.1 Con: 66.5 | Advanced or locally advanced PCa with ADT or surgical castration ≥ 6 months | Supervised football training | Duration: 12 Frequency: week 1–8: 2 week 9–12: 3 | Overweight Cardiovascular | Dual X-ray absorptiometry: lean body mass, android, gynoid total body fat mass: BMI; waist circumference; hip circumference VO2 max: 4-min walking test; incremental test to exhaustion Pulmonary gas exchange measurements Heart rate monitors |
| Winters- stone [ | Int: 29 Con: 22 Total: 51 | Int: 69.9 Con: 70.5 | Localized or metastatic PCa currently receiving ADT | Int: Supervised + unsupervised resistance exercise Cont: Stretching | Duration: 52 Frequency: 3 | Fatigue Overweight Insulin resistance Quality of life | SCFS BMI Dual X-ray absorptiometry: Fat mass; Bone-free lean mass; trunk fat mass Blood biomarkers: insulin; IGF-1 LLFDI |
| Cormie [ | Int: 32 Con: 31 Total: 63 | Int: 69.6 Con: 67.1 | PCa within first 10 days on ADT and anticipated to remain on ADT ≥ 3 months | Supervised aerobic + resistance exercise | Duration: 12 Frequency: 2 | Fatigue Overweight Cardiovascular Osteoporosis Libido Insulin resistance Depression Quality of life | FACIT-fatigue Dual X-ray absorptiometry: body lean mass, fat mass, appendicular lean mass, trunk fat mass, visceral fat mass Blood biomarkers: CRP VO2 max: 400-m walk test RR: brachial Dual X-ray absorptiometry: BMD: hip, lumbar spine, whole body Blood biomarkers: alkaline phosphatase, P1NP, N-telopeptide, N-telopeptide/creatinin QLQ-PR25 Blood biomarkers: Insulin, glucose BSI-18 QLQ-PR25; SF-36 |
| Nilsen [ | Int: 28 Con: 30 Total: 58 | Int: 66 Con: 66 | Locally advanced PCa receiving RT after neo-adjuvant ADT for 6 months and adjuvant ADT 9–36 months | Supervised resistance exercise | Duration: 16 Frequency: 3 | Overweight Fatigue Osteoporosis Cardiovascular Quality of life | Dual x-ray absorptiometry: lean body mass, Regional LBM: (trunk, lower extremities, upper extremities, appendicular skeletal mass), fat mass, fat percentage, body mass, BMI EORTC- QLQ-C30 Dual X-ray absorptiometry: BMD: total, total lumbar spine, hip, trochanter and femoral neck Shuttle walk test EORTC-QLQ-C30 |
| O’neill [ | Int: 47 Con: 47 Total: 94 | Int: 69.7 Con: 69.9 | PCa treated ADT for ≥ 6 months and planned to continue for ≥ 6 months or commencing to start ≥ 6 months | Aerobic exercise + dietary advice | Duration: 26 Frequency: Walking: 5 | Overweight Fatigue Cardiovascular Quality of life | Weight, BMI, fat mass, lean muscle mass, waist-to-hip ratio, mid-upper arm muscle area Fat mass: Skinfold thickness FSS 400-m walk test FACT-P; PSS |
| Stefanopoul ou [ | Int: 33 Con: 35 Tot: 68 | Int: 68.0 Con: 68.7 | Localized or metastatic PCa undergoing ADT | CBT booklet | Duration: 4 | Hot Flushes Depression Quality of life | HFNS HADS EORTC-QLQ-C30; EORTC- QLQ-PR25 |
| Gilbert [ | Int: 25 Con: 25 Total: 50 | Int: 70.1 Con: 70.4 | PCa receiving ADT ≥ 6 months + radiotherapy | Supervised + unsupervised aerobic, balance, resistance exercise + Dietary advice: healthy-eating seminars | Duration 12 Frequency: Training: 3 Diet: 1 × 2 week | Overweight Cardiovascular | BMI, weight Blood biomarkers: total cholesterol, LDL, HDL, triglycerides RR: Brachial artery FMD, GTN-arterial dilatation VO2 max: Exercise tolerance: walking test |
| Nilsen [ | Int: 16 Con: 15 Total: 31 | Int: 66 Con: 65 | Locally advanced PCa receiving RT after neo-adjuvant ADT for 6 months and adjuvant ADT 9-36 months | Supervised resistance exercise | Duration: 16 Frequency: 3 | Overweight | Muscles biopsies m. Vastus lateralis: protein concentrations, HSP70, Alpha B-crystalline, HSP27, HSP27, HSP60, C OXIV, Citrate synthase Ubiquitin |
| Nilsen [ | Int: 12 Con: 11 Total: 23 | Int: 67 Con: 64 | Locally advanced PCa receiving RT after neo-adjuvant ADT for 6 months and adjuvant ADT 9–36 months | Supervised resistance exercise | Duration: 16 Frequency: 3 | Overweight | Muscle biopsies m. Vastus lateralis: histology, muscle fiber CSA, myonuclei, satellite cells, protein concentrations |
| Sajid [ | EXCAP: 6 Wii-fit: 8 Con: 5 Total: 19 | EXCAP: 75.7 Wii-fit 77.5 Con: 71.8 | PCa with ADT, ADT combined with RT | EXCAP: Unsupervised aerobic exercise + resistance exercise Wii-fit: Multi- component exercise on WII | Duration: 6 Frequency: 5 | Fatigue Overweight | SPPB Dual X-ray absorptiometry: body fat mass, body lean mass, skeletal muscle mass |
| Uth [ | Int: 29 Con: 28 Total: 57 | Int: 67.1 Con: 66.5 | Locally advanced or metastatic PCa undergoing ADT for ≥ 6 months | Supervised football exercise | Duration: 32 Frequency: week 1–: 2 week 9–12: 3 week 12–32: 2 | Overweight Osteoporosis | Dual X-ray absorptiometry: body lean mass, fat mass, percentage fat mass, Dual x-ray absorptiometry: BMD: total hip, femoral, lumbar spine, Blood samples: P1NP, osteocalcin, CTX |
| Uth [ | Int: 29 Con: 28 Total: 57 | Int: 67.1 Con: 66.5 | Locally advanced or metastatic Pca undergoing ADT for ≥ 6 months | Supervised football exercise | Duration: 12 Frequency: wk 1-8: 2 wk 9-12: 3 | Osteoporosis | Dual X-ray absorptiometry BMC: total body, legs BMD: total body, legs Blood biomarkers: CTX, P1NP, osteocalcin |
| Kim [ | Int: 26 Con: 25 Total: 51 | Int: 70.5 Con: 71.0 | PCa Stage I to III receiving ADT | Unsupervised strength training + resistance exercise | Duration: 26 Frequency: 3-5 | Osteoporosis Quality of life | Dual x-ray absorptiometry: total BMD, regional BMD: Total hip, femur neck, lumbar spine, Blood samples: bs-ALP, Ntx FACT-P |
| Taaffe [ | ILRT: 58 ART: 54 Con: 51 Total:163 | ILRT:68. 9 ART: 69 Con: 68.4 | PCa with ADT exposure ≥ 2 months, anticipated to receive ADT following 12 months | Supervised impact + resistance exercise (ILRT) Supervised + unsupervised aerobic + resistance exercise (ART) | Duration: 52 Frequency: ILRT + AER: 2 | Fatigue Cardiovascular | EORTC-QLQ-C30; SF-36 400 m walk |
| Wall et al. [ | Int: 50 Con: 47 Total: 97 | Int: 69.1 Con: 69.1 | Localized PCa on ADT for ≥ 2 months | Supervised and unsupervised aerobic + resistance exercise | Duration: 26 Frequency: 2 | Overweight Cardiovascular Insulin resistance | Dual X-ray absorptiometry: lean body mass, fat mass, trunk fat mass, percentage body fat, appendicular fat mass, weight Blood biomarkers: CRP Respiratory gas analysis: fat oxidation, carbohydrate oxidation Blood samples: LDL; HDL; cholesterol, triglycerides VO2Max; RR: brachial Applanation tonometry: arterial stiffness, aortal blood pressure Carotid-to-radial pulse-wave Blood biomarkers: Insulin: Hba1c, glucose |
| Dawson [ | Int: 13 Con: 19 Total: 32 | Pro: 68.6 Con: 66.3 | PCa with ADT | Supervised resistance training | Duration: 12 Frequency: 3 | Fatigue Overweight Cardiovascular Insulin resistance Depression Quality of life | BFI Dual X-ray: appendicular skeletal mass, lean body mass, fat mass, percentage body fat, waist circumference Systolic blood pressure, diastolic blood pressure Blood biomarkers: Glucose CES-D FACT-G; FACT-P |
RCTs randomized controlled trials; Int intervention group, Con control group, PCa prostate cancer, ADT androgen deprivation therapy, RT radiotherapy, Ven/V venlafaxine, Soy/S soy protein, physical examinations, BMI body mass index, LBM lean body mass, BMD bone mineral density, BMC bone mineral content, PPB positive pressure, breathing, RR blood pressure, OGTT oral glucose tolerance test, VO2 max maximal oxygen consumption, FMD flow-mediated dilatation, GTN-arterial dilatation glyceryl trinitrate-arterial dilatation
Blood biomarkers IGF-1: Insulin Growth Factor-1, IGFBP: Insulin-Like Growth Factor-Binding Peptide, IGFBP-1: Insulin-Like Growth Factor-Binding Peptide-1, IGFBP-3: Insulin-Like Growth Factor-Binding Peptide-3, Hba1c: Glycosylated Hemoglobin type A1c, LDL: Low Density Lipoprotein, HDL: High Density Lipoprotein, CRP: C-Reactive Protein, CTX: Cyclophosphamide, P1NP: Procollagen Type 1, bs-ALP: bone-specific Alkaline Phosphatase, NTX: N-Telopeptide of type I collagen
Questionnaires CES-D: Center for Epidemiologic Studies Depression scale, HADS: Hospital Anxiety and Depression Scale, DAS scale: Depression, Anxiety and Stress scale, BFI: Big Five Inventory, BSI-18: Brief Symptom Inventory 18, FSS: Fatigue Severity Scale, FACT-P: Functional Assessment of Cancer Therapy-Prostate; FACT-G: Functional Assessment of Cancer Therapy General; FACT-F: Functional Assessment of Cancer Therapy Fatigue POMS: Profile Of Mood Status; EIFI-exhaustion: The Exercise-Induced Feeling Inventory EORTC-QLQ-C30: European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30, EORTC-QLQ-PR25: European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Prostate-Specific 25-item, SF-36: short-form health survey (36), EPIC: Expanded Prostate Cancer Index, HFSS: Hot Flashes Severity Score, HFNS: Hot Flushes and Night Sweats, HFSSS: Hot Flushes Severity Symptom Score, PAIR inventory: Personal Assessment of Intimacy in Relationships, SPPB: Short Physical Performance Battery, IIEF: International Index of Erectile Function, WSFS: Watts Sexual Functioning Scale; PORPUS: Patient-Oriented Prostate Utility Scale, PSS: Perceived Stress Scale, LLFDI: Late Life Function and Disability Instrument, STAI: State-Trait Anxiety Inventory
Overview of RCTs testing mitigation strategies for ADT categorized per side effect
| Side effect | Intervention | Study | Outcomes | Methods to measure outcome |
|---|---|---|---|---|
| Quality of life | Aerobic training | Santa Mina et al. [ | No difference | PRO (FACT-P; PORPUS) |
| Aerobic training + dietary advice | O’neill et al. [ | Improvement in the individual functional well-being subscale ( | PRO (FACT-P; PSS) | |
| Aerobic + Resistance training | Culos-Reed et al. [ | No difference | PRO (EORTC-QLQ-C30, EPIC) | |
| Galvao et al. [ | Significant improvement for general health ( | PRO (QLQ-C30; SF-36) | ||
| Bourke et al. [ | No difference | PRO (FACT-P; FACT-G) | ||
| Cormie et al. [ | Significant improvement in social functioning ( | PRO (QLQ-PR25; SF-36) | ||
| Aerobic + resistance + dietary advice | Cormie et al. [ | Significant difference in perceived general health ( | PRO (SF-36) | |
| Bourke et al. [ | Significant improvement after 12 weeks ( | PRO (FACT-P) | ||
| Cognitive behavioral therapy | Stefanopoulou et al. [ | No differences | PRO (EORTC-QLQ-C30; EORTC-QLQ-PR25) | |
| Resistance training | Segal et al. [ | Increase in QOL, compared with a decrease for the control group ( | PRO (FACT-P) | |
| Taylor et al. [ | No differences | PRO (SF-36, STAI) | ||
| Santa Mina et al. [ | No differences | PRO (FACT-P; PORPUS) | ||
| Nilsen et al. [ | No differences | PRO (EORTC-QLQ-C30) | ||
| Kim et al. [ | No differences | PRO (FACT-P) | ||
| Dawson et al. [ | Significant improvement in quality of life measured with FACT-G ( | PRO (FACT-G; FACT-P) | ||
| Soy protein | Sharma et al. [ | No differences | PRO (SF-36) | |
| Vitolins et al. [ | Improvements in emotional ( | PRO (FACT-P; FACT-G) | ||
| Depression | Aerobic + resistance training | Culos-Reed et al. [ | No differences | PRO (CES-D) |
| Santa Mina et al. [ | No differences | PRO (FACT-F) | ||
| Cormie et al. [ | No differences | PRO (BSI-18) | ||
| Cognitive behavioral therapy | Stefanopoulou et al. [ | No differences | PRO (HADS) | |
| Educational support program | Taylor et al. [ | No differences | PRO (CES-D) | |
| Lifestyle activity program | Taylor et al. [ | No differences | PRO (CES-D) | |
| Resistance training | Dawson et al. [ | No differences | PRO (CES-D) | |
| Fatigue | Aerobic training | Santa Mina et al. [ | No differences | PRO (FACT-F) |
| Aerobic training + dietary advice | O’neill et al. [ | No differences | PRO (FSS) | |
| Aerobic + resistance training | Cormie et al. [ | Significant reduction ( | PRO (FACIT-fatigue) | |
| Culos-Reed et al. [ | No difference | PRO (FSS) | ||
| Galvao et al. [ | Significant reduction in fatigue ( | PRO (QLQ-C30, SF-36) | ||
| Santa Mina et al. [ | No differences | PRO (FACT-F) | ||
| Sajid et al. [ | EXCAP: Significant reduction ( | PRO (SPPB) | ||
| Taaffe et al. [ | Significant reduction in fatigue ( | PRO (EORTC-QLQ-C30; SF-36) | ||
| Aerobic + resistance training + dietary advice | Bourke et al. [ | Significant reduction at 12 weeks ( | PRO (FACT-F) | |
| Bourke et al. [ | Significant reduction at 12 weeks ( | PRO (FACT-P) | ||
| Impact + resistance training | Taaffe et al. [ | Significant reduction of fatigue ( | PRO (EORTC-QLQ-C30; SF-36) | |
| Resistance training | Segal et al. [ | Significant reduction ( | PRO (FACT-F) | |
| Sharma et al. [ | Significant reduction after 12 weeks ( Per-group analysis: significant reduction after 24 weeks ( | PRO (SF-36) | ||
| Santa Mina et al. [ | No differences | PRO (FACT-F) | ||
| Nilsen et al. [ | No differences | PRO (EORTC- QLQ-C30) | ||
| Dawson et al. [ | No differences | PRO (BFI) | ||
| Soy protein | Sharma et al. [ | No differences | PRO (SF-36) | |
| Decreased libido + sexual function | Aerobic + resistance training | Culos-Reed et al. [ | No difference between groups or effect over time in sexual function | PRO (EPIC) |
| Cormie et al. [ | Significant difference in percentage of major interest in sex ( | PRO (QLQ-PR25) | ||
| Cormie et al. [ | Significant less decline in sexual function ( Per-group-analysis over time: decline in sexual activity ( | PRO (QLQ-PR25) | ||
| Information booklet | Walker et al. [ | No significant differences. Sexual activity at baseline: 64.3% versus 38.5% (control), after 6 months: 25% versus 0% (control) | PRO (PAIR inventory: DAS scale, sexual activity) | |
| Soy protein | Sharma et al. [ | No differences | PRO (IIEF, WSFS) | |
| Overweight | Aerobic training | Hvid et al. [ | Body composition: no differences Per-group analysis: reduction in BMI ( Blood biomarkers: no differences Per-group analysis: Increase in HDL over time. No differences in LDL, total cholesterol, triglycerides | Body composition and blood biomarkers |
| Santa Mina et al. [ | No differences | Body composition | ||
| Aerobic training + dietary advice | O’neill et al. [ | Body composition: significant reduction (all No difference in lean body mass or mid-upper arm muscle area | Body composition | |
| Aerobic + resistance training | Culos-Reed et al. [ | Body composition: significant reduction in waist girth ( Per-group analysis: no difference in BMI | Body composition | |
| Galvao et al. [ | Body composition: significant increase in total lean mass ( Blood biomarkers: Significant decrease in CRP ( | Body composition and blood biomarkers | ||
| Cormie et al. [ | Body composition: significant reduction in appendicular lean mass ( Blood biomarkers: significant reduction in HDL total cholesterol ratio ( | Body composition and blood biomarkers | ||
| Sajid et al. [ | EXCAP: Body composition: no differences Wii-fit: Body composition: decrease in lean mass for the Wii-fit group ( | Body composition | ||
| Wall et al. [ | Body composition: increase in lean body mass ( Blood biomarkers: no differences | Body composition and blood biomarkers | ||
| Aerobic + resistance training + dietary advice | Bourke et al. [ | No differences | Body composition | |
| Bourke et al. [ | No differences | Body composition | ||
| Gilbert et al. [ | Body composition: significant increase in skeletal muscle mass ( Blood biomarkers: no differences | Body composition and blood biomarkers | ||
| Educational support program | Taylor et al. [ | No differences | Body composition | |
| Football training | Uth et al. [ | Significant increase in lean body mass ( Per-group analysis: significant increase in lean body mass ( | Body composition | |
| Uth et al. [ | No differences | Body composition | ||
| Resistance exercise | Uth et al. [ | No differences | Body composition | |
| Segal et al. [ | No differences | Body composition | ||
| Santa Mina et al. [ | No differences | Body composition | ||
| Winters-stone [ | Significant reduction in total fat mass in covariance analysis ( No significant change in body lean mass, percentage body fat, weight or trunk fat mass | Body composition | ||
| Nilsen et al. [ | Significant increase in LBM in lower extremities ( | Body composition | ||
| Nilsen et al. [ | No significant difference in mitochondrial proteins or indicators of muscle cellular stress: HSP70 B-crystallin; ubiquitin; ubiquittinated proteins Per-group analysis: change over time in HSP70 ( | Muscles biopsies m. Vastus lateralis: protein concentrations, HSP70, Alpha B-crystalline, HSP27, HSP27, HSP60, COXIV, Citrate synthase Ubiquitin | ||
| Nilsen et al. [ | Significant change in total muscle fiber in favor for intervention group ( Significant increase in type II fibers for intervention group ( | Muscle biopsies m. Vastus lateralis: histology, muscle fiber CSA, myonuclei, satelite cells, protein concentrations | ||
| Dawson et al. [ | Significant increase in lean mass, appendicular skelet mass ( Blood biomarkers: No difference | Body composition | ||
| Hot flushes | Cognitive Behavioral Therapy | Stefanopoulou et al. [ | Decreased hot flashes problem rating ( No difference at 32 weeks | PRO (HFNS) |
| Soy protein | Sharma et al. [ | Difference in favor of the placebo group at 12 weeks ( Per-group analysis: no difference in vasomotor symptoms | PRO (Blatt-Kupperman scale) | |
| Vitolin et al. [ | No differences Per-group analysis: significant decrease of vasomotor symptoms ( | PRO (HFSS, HFSSS) | ||
| Gynaecomastia | Aerobic training | Santa Mina et al. [ | No difference | Body composition |
| Resistance training | Santa Mina et al. [ | No difference | Body composition | |
| Cardiovascular | Aerobic training | Hvid et al. [ | No significant difference in VO2 max (ml(O2)/min per kg), VO2max (ml(O2)/min Per-group analysis: increase in VO2 max (ml(O2)/min per kg) ( | Physical test (VO2max) |
| No difference | ||||
| Santa Mina et al. [ | No difference | Physical test (VO2max) | ||
| Aerobic training + dietary advice | O’neill et al. [ | Significant change (P = 0.001) | Physical test (6-m walk test) | |
| Aerobic + resistance training | Culos-Reed et al. [ | No difference Per-group analysis: significant reduction of systolic blood pressure (P = 0.011) and diastolic blood pressure (P = 0.004) | Blood pressure | |
| Galvao et al. [ | No difference | Physical test (400 m walk test) | ||
| Cormie et al. [ | Significant increase in VO2 max ( No change in blood pressure | Physcial test (VO2 max: 400-m walk test) Blood pressure | ||
| Taaffe et al. [ | No differences Per-group analysis: cardiovascular fitness improved ART: | Physical test (400 m walk) | ||
| Wall et al. [ | Significant increase in VO2 Max (L min) and VO2 Max (ml/kg) ( No change in RMR, carbohydrate oxidation, peripheral systolic, diastolic RR or MAP, central diastolic RR or MAP, peripheral augmentation index, central augmentation pressure, central augmentation, index, pulse-wave velocity | Physical test (Respiratory gas analysis, VO2 Max), blood pressure, blood samples | ||
| Aerobic + resistance training + dietary advice | Bourke et al. [ | Significant improvement in aerobic exercise tolerance at 12 weeks ( No difference in systolic blood pressure | Physcial test (aerobic exercise tolerance), blood pressure | |
| Aerobic, balance, resistance exercise + dietary advice | Gilbert et al. [ | Treadmill walk time improved at 12 and 24 weeks ( pressure | Physical test (VO2 max, exercise tolerance: walking test), blood pressure | |
| Football training | Uth et al. [ | No significant difference between groups Per-group -analysis: VO2 max increased in the intervention group (1.0 ml/kg/min) | Physical test (VO2 max: 4-min walking test; incremental test to exhaustion, pulmonary gas exchange measurements; heart rate monitors) | |
| Impact + resistance training | Taaffe et al. [ | No differences | Physical test (400 m walk) | |
| Resistance training | VO2max improvement ( | |||
| Santa Mina et al. [ | Significant improvement compared to control group | Physical test (VO2 max) | ||
| Dawson et al. [ | No differences | Blood pressure | ||
| Aerobic training | Hvid et al. [ | No difference in fasting glucose, glucose AUC or insulin AUC compared to control group Per-group analysis: significant change in fasting glucose ( | Physical test (VO2 Max OGTT Euglycemic– hyperinsulinemic clamp), blood biomarkers | |
| Aerobic + resistance training | Galvao et al. [ | No differences | Blood biomarkers | |
| Cormie et al. [ | No differences | Blood biomarkers | ||
| Wall et al. [ | Significant change for glucose ( | Blood biomarkers | ||
| Aerobic + resistance training + dietary advice | Bourke et al. [ | No differences | Blood biomarkers | |
| Resistance training | Winters-stone [ | No differences | Blood biomarkers | |
| Dawson et al. [ | No differences | Blood biomarkers | ||
| Aerobic + resistance training | Cormie et al. [ | No differences | Body composition, blood biomarkers | |
| Football training | Uth et al. [ | Bone mineral content: significant increment in total body BMC ( Bone mineral density: no differences Blood biomarkers: significant change P1NP ( | Body composition, blood biomarkers | |
| Uth et al. [ | Bone mineral density: significant increment in left total hip ( Blood biomarkers: no differences | Body composition, blood biomarkers | ||
| Resistance training | Nilsen et al. [ | No differences | Body composition | |
| Kim et al. [ | No differences | Body composition |
Methodological quality assessment tool for randomized controlled trials
| Random sequence generation (Selection bias) | Allocation concealment (Selection bias) | Blinding of participants and personnel (performance bias) | Blinding of outcome assessment (attrition bias) | Incomplete outcome data (attrition bias) | Selective reporting (reporting bias) | Other bias | ||
|---|---|---|---|---|---|---|---|---|
| Segal [ | 2003 | + | + | − | ? | − | + | + |
| Taylor [ | 2006 | − | − | − | + | + | + | − |
| Sharma [ | 2009 | + | + | + | + | ? | + | − |
| Culos-Reed [ | 2010 | + | + | − | + | ? | + | − |
| Galvao [ | 2010 | + | + | − | − | + | + | + |
| Bourke [ | 2011 | + | ? | − | + | + | ? | ? |
| Cormie [ | 2013 | + | + | − | ? | + | + | + |
| Hvid [ | 2013 | − | − | − | + | − | + | − |
| Santa Mina [ | 2013 | ? | + | − | + | + | + | − |
| Vitolins [ | 2013 | + | + | + | + | − | − | − |
| Walker [ | 2013 | ? | ? | − | ? | + | + | − |
| Bourke [ | 2014 | + | + | − | − | + | + | + |
| Uth [ | 2014 | + | + | − | + | + | + | − |
| Winters-Stone [ | 2015 | ? | ? | − | + | + | + | − |
| Cormie [ | 2015 | + | + | − | ? | + | + | + |
| Nilsen [ | 2015 | + | ? | − | + | + | + | + |
| O’Neill [ | 2015 | + | + | − | − | + | + | ? |
| Stefanopoulou [ | 2015 | + | + | − | + | − | + | − |
| Gilbert [ | 2016 | + | + | − | + | + | + | + |
| Nilsen [ | 2016 | + | ? | − | + | − | ? | − |
| Nilsen [ | 2016 | + | ? | − | + | − | ? | − |
| Sajid [ | 2016 | + | + | − | + | − | + | + |
| Uth [ | 2016 | + | + | − | + | + | ? | − |
| Uth [ | 2016 | + | + | − | + | − | + | − |
| Kim [ | 2017 | + | + | − | − | − | + | − |
| Taaffe [ | 2017 | + | + | − | + | − | + | ? |
| Wall Dawson [ | 2017 2018 | + + | + + | − − | + − | − + | + ? | + + |
Risk of bias summary for each trial included in the systematic review as evaluated by authors
+ low risk of bias; ? Some concerns are risk of bias; − high risk of bias